Source link : https://www.newshealth.biz/health-news/case-strengthens-for-cardiac-myosin-inhibitor-in-sequoia-hcm/
Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for another cardiac myosin inhibitor in obstructive hypertrophic cardiomyopathy (HCM). In these randomized trial analyses, aficamten significantly improved the following outcomes compared with placebo: Relief from limiting symptoms (71% vs 42% ≥1 improvement in New York Heart Association functional […]
Author : News Health
Publish date : 2024-09-30 18:09:10
Copyright for syndicated content belongs to the linked Source.
Categories